New research finds that stopping GLP-1 drugs like semaglutide and tirzepatide can quickly erase heart-protection gains, with continuous treatment showing the strongest benefits and interruptions leaving lasting harm even after restarting.
GLP-1 receptor agonists have become central in treating type 2 diabetes and obesity because they do more than shrink waistlines; they improve cholesterol, blood pressure, inflammation and insulin sensitivity. A large observational study of more than 333,000 U.S. veterans tracked outcomes over roughly three years to see what happens when patients quit these medications.
The team found steady use for three years produced an 18% reduction in cardiovascular events, a meaningful win for long-term risk reduction. But stopping the drugs produced a rapid backslide: six months off raised risk by 4%, one year by 14%, and two years off by 22%.
“Many people are excited to start GLP-1s, but many stop within a few months,” Ziad Al-Aly, senior clinical epidemiologist at WashU Medicine, told Fox News Digital. “Some research looked at weight regain after people stop — we wanted to know what happens to heart health when people stop.”
“We found that stopping erodes the heart protection these drugs provide,” Al-Aly said. “It took three years of continuous use to achieve an 18% reduction in heart attack, stroke and death — but that protection erodes fast.” The study showed restarting helped but could not fully recover what was lost.
“Restarting helped, but it didn’t fully restore the protection of uninterrupted use,” the researcher emphasized. “Discontinuation leaves a lasting scar. That tells us the damage from stopping isn’t fully reversible, and that has real implications for the millions of people cycling on and off these drugs.”
Independent cardiology experts noted this pattern fits chronic disease management: medication interruptions often allow the underlying disease to resume. “When treating patients with chronic diseases, the primary objective is long-term success,” the Maryland-based doctor said. “This is achieved through behavioral modification, lifestyle changes, improved heart-healthy diets and medical therapy.”
The investigators also cautioned about the study’s limits: observational design means association, not absolute proof of causation, and the cohort skewed toward older male veterans, which may not represent the broader public. “The patients in this study were at a higher risk of developing coronary artery disease,” Serwer pointed out. “Many individuals taking GLP-1 medications do so for weight loss, and may not necessarily have significant cardiovascular risk factors, such as diabetes, hypertension or hyperlipidemia.”
Researchers highlighted that the dangers of stopping are often silent, not dramatic. “When people stop GLP-1 drugs, it’s not just weight that comes back,” Al-Aly said. “They experience a resurgence in inflammation, blood pressure, cholesterol and insulin resistance.” He warned, “It doesn’t announce itself until it surfaces in the ER as a heart attack or a stroke. We think of this as a form of ‘metabolic whiplash,’ and our data suggest it is detrimental to heart health.”
Clinicians recommend pairing drug therapy with durable lifestyle changes to protect long-term outcomes and to discuss risks openly before starting or stopping treatment. “It is crucial to adopt a holistic approach that emphasizes lifestyle modifications, diet and exercise,” Serwer said. “All medications have their advantages and disadvantages. It is essential to engage in a comprehensive discussion with your medical providers to carefully evaluate the potential benefits and risks.”
